Tag:

Biotech IPO

Latest Headlines

Latest Headlines

Sage up-sizes its ambition on the eve of a much-watched IPO

Biotech luminary Sage Therapeutics is boosting the size of its planned IPO, upping its share offering and expected price range as investors look to its Wall Street debut as a bellwether for the industry.

Fresh off Phase III success, Otonomy shoots for an $86M IPO

San Diego biotech Otonomy isn't biding its time, filing to go public in an $86.3 million IPO just three days after unveiling positive Phase III results for its lead drug.

IPO hopefuls swing for $126.5M and hope biotech's window stays open

After two consecutive quarters of mostly bullish biotech debuts, two drugmakers are lining up IPOs in hopes the market stays drug-friendly, seeking a combined $126.5 million to bankroll treatments for cancer and metabolic disease.

UPDATED: Biotech IPO scorecard: Hits, runs and errors mount in mixed Q2

It takes a scorecard to keep up with the biotech IPO action these days. Four of the 8 companies planning to go public in the U.S. this week are biotechs, including Minerva and Syndax, and the crush of companies at the Nasdaq gate is making it increasingly hard for all of them to find a large enough group of investors to back their play.

Two more biotechs roll the IPO dice as the market sputters

Even though the biotech IPO market has been sputtering under the weight of a wave of new offerings and some heightened skepticism of what's being put in front of investors these days, two more biotechs have laid out plans to raise a total of some $150 million.

Dutch biotech arGEN-X plots an IPO as it pads its list of partners

Fresh off its latest R&D partnership, Dutch antibody specialist arGEN-X is planning to go public in Brussels, looking to raise cash and advance its proprietary pipeline.

Syndax sets terms for a $69M IPO to support its 'breakthrough' drug

Syndax Pharmaceuticals is looking to raise $69 million in an IPO, planning to move 4.3 million shares at between $13 and $15 apiece.

AstraZeneca partner Ardelyx pitches $69M IPO

Ardelyx retained U.S. co-promotion rights for tenapanor when it did its deal with AstraZeneca back in 2012.

Pioneering CAR-T biotech upstart plans to leapfrog into a $115M IPO

Can a fledgling biotech still plotting early-stage studies of its cutting-edge cancer drug technology mount a successful IPO by mapping a radically short trip to the FDA?

InDex mulls Swedish IPO, Circassia backer posts profit jump, U.K. targets bio investment

This week's edition of the EuroBiotech Report brings fresh evidence that the U.S. biotech IPO boom has landed on European shores, with other companies from the stable of Circassia-backer Imperial Innovations considering going public and InDex Pharmaceuticals preparing to test the waters in Sweden. And more.